ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 142 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q4 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $205,090 | -44.0% | 8,027 | -37.2% | 0.00% | -50.0% |
| Q2 2023 | $366,559 | +164.0% | 12,781 | +120.6% | 0.00% | +100.0% |
| Q1 2023 | $138,858 | +41.3% | 5,793 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $98,249 | +34.6% | 5,793 | +18.0% | 0.00% | – |
| Q3 2022 | $73,000 | -6.4% | 4,911 | -0.5% | 0.00% | – |
| Q2 2022 | $78,000 | -44.3% | 4,938 | -5.0% | 0.00% | -100.0% |
| Q1 2022 | $140,000 | -27.5% | 5,200 | -0.5% | 0.00% | 0.0% |
| Q4 2021 | $193,000 | -22.8% | 5,226 | +0.0% | 0.00% | 0.0% |
| Q3 2021 | $250,000 | +39.7% | 5,225 | -1.0% | 0.00% | 0.0% |
| Q2 2021 | $179,000 | -16.0% | 5,277 | +2.3% | 0.00% | 0.0% |
| Q1 2021 | $213,000 | +134.1% | 5,160 | +145.8% | 0.00% | 0.0% |
| Q4 2020 | $91,000 | +23.0% | 2,099 | +21.9% | 0.00% | 0.0% |
| Q3 2020 | $74,000 | +100.0% | 1,722 | +119.1% | 0.00% | – |
| Q2 2020 | $37,000 | – | 786 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |